Mergers and acquisitions (M&A) continue to reshape the medical laboratory industry and overall healthcare landscape in 2025. While market conditions remain complex, laboratories that prepare strategically can attract buyers, command stronger valuations, and avoid costly pitfalls.
In an Aug. 20, 2025, webinar hosted by Lighthouse Lab Services, the following panel of legal and regulatory experts shared their perspectives on what drives successful transactions in the current climate:
- Danielle Tangorre and Leslie Levinson – Partners and attorneys at Robinson + Cole with deep experience in healthcare transactions and compliance.
- Derek Taylor – Managing Vice President at Laboratory Nexus, specializing in buyer/seller connections.
- Jon Harol – Founder of Lighthouse Lab Services, providing consulting and due diligence support for labs.
Below are the top takeaways from this session.
Listen to the full webinar here.
Market Conditions: Cautious Optimism Amid Uncertainty
At the start of 2025, expectations for strong M&A activity were high following the resolution of election-year uncertainty. However, factors such as stalled interest rate cuts, broader economic volatility, and potential Medicaid reductions have created pauses in dealmaking.
Despite this, healthcare, particularly the laboratory sector, remains attractive to investors as a defensive, resilient market. A potential federal interest rate cut later in the year may further accelerate transactions.
“Healthcare continues to be viewed by most as a defensive investment and a little bit more immunized in some of the turmoil we’re seeing in other sectors of the market.” – Les Levinson
Who’s Buying Laboratories in 2025?
Speakers noted an expanding and diverse buyer pool:
- Institutional players and public companies like Quest and Labcorp continue consolidating market share.
- Private equity firms remain active, often pursuing roll-up strategies.
- Family offices and international buyers see labs as an opportunity for stable, long-term returns.
- Pharmaceutical and device companies are acquiring labs to pair diagnostics with therapeutics or streamline FDA pathways.
- Other laboratories are targeting strategic acquisitions to expand geography or add specialized testing capabilities.
“The most common buyer we’re seeing right now is actually other laboratories, groups looking for strategic acquisitions, sometimes to expand geographically and sometimes to move into more specialized areas like molecular genetics.” – Derek Taylor
Hot Spots: Oncology, Genetics, and AI
Key areas of acquisition interest include:
- Oncology and molecular diagnostics – Reflecting rising demand for personalized medicine.
- Next-generation sequencing (NGS) and genetic testing.
- AI-enabled genomics and digital pathology – Labs with strong data and technology offerings are commanding attention.
- Roll-ups of small, profitable labs – Particularly those with clean compliance records and scalable payer contracts.
“There’s been a lot of discussion in the marketplace about harnessing your data; whether that’s pairing with pharmaceutical companies, partnering with AI firms, or entering joint ventures with digital pathology groups.” – Danielle Tangorre
Preparing Your Lab for Sale
The panel stressed that preparation is the single most important factor in a successful transaction. Buyers are increasingly risk-averse and conduct deeper due diligence than in years past. To stand out, labs should:
- Conduct internal audits of billing, coding, and compliance. Mock audits and quality of earnings (QoE) reports can prevent deal-breaking surprises.
- Organize payer contracts and licensing documentation well in advance. Missing contracts or unclear change-of-ownership clauses can derail negotiations.
- Assess regulatory risks tied to referral arrangements, marketing practices, or reimbursement strategies.
- Build a strong internal and external deal team (executives, accountants, attorneys, consultants) to manage the process while operations continue.
(Learn how Lighthouse Lab Services supports labs with pre-sale mock inspections and RCM due diligence.)
“Having a clean company is going to make your acquisition opportunity more likely to succeed. Buyers are being more discriminating, and the rock-turning exercises are more rigorous than ever.” – Les Levinson
Deal Structures and Negotiation Considerations
Not all transactions follow the same playbook. Key factors include:
- Deal type – Asset purchases, stock purchases, or joint ventures, depending on contracts and liability concerns.
- Consideration mix – Many deals blend cash, equity, and earn-outs tied to performance metrics.
- Letters of intent (LOIs) – Setting clear expectations early (valuation, exclusivity, tax considerations, timelines) helps avoid conflict later.
- Disclosure schedules – Thorough, accurate documentation is tedious but critical to protecting sellers post-closing.
“Don’t just sign a letter of intent if it’s presented to you—make sure your advisors review it and negotiate provisions. That step pays huge dividends once you get to definitive agreements.” – Les Levinson
Post-Closing Matters: What Happens After the Deal?
Even after closing, labs should expect additional steps:
- Working capital true-ups within 60–90 days to ensure financial targets are met.
- Claims and indemnifications if representations and warranties are challenged.
- Employee integration and retention – Communicating clearly with staff at the right time helps preserve value.
- Smooth transition planning – Ensures the buyer gets what they expected and avoids operational disruption.
“Time kills deals. If you don’t take the process seriously, you risk wasting a lot of time and ending up with nothing at the end.” – Derek Taylor
Final Thoughts
The laboratory M&A landscape in 2025 offers both opportunities and challenges. Buyers are available, but they are also more discriminating, requiring sellers to demonstrate operational strength, compliance readiness, and financial transparency.
Whether you are considering selling your laboratory, exploring acquisitions, or simply want to understand market dynamics, preparation and working with the right advisory team are essential. Contact us today for a complimentary consultation if you are preparing for a lab sale or merger and have questions.
